Pee and blood may replace painful muscle biopsies for muscular dystrophy
NCT ID NCT05020002
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find less invasive ways to measure disease activity in myotonic dystrophy by looking for RNA markers in blood and urine instead of taking muscle biopsies. Researchers will compare samples from 215 people with and without the condition to see if these markers can reliably track disease severity. The goal is to develop a simple test that could make monitoring the disease easier and more comfortable for patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02129, United States
-
University of Texas Southwestern
RECRUITINGDallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we measure the progression of childhood myotonic dystrophy well enough to test new therapies?
- Scientists hunt for biomarkers to unlock DM1 treatments
- Could virtual reality help kids with a rare muscle disease read emotions better?
- New study tracks Long-Term safety of muscle stiffness drug namuscla
- No travel needed: new study uses video calls to uncover genetic secrets of childhood muscle disease
- Brain scans reveal diabetes link to cognitive decline in rare disease